Taro Recalls Topicort Cream Due to Subpotent Drug Hazard
Taro Pharmaceuticals recalls Topicort (desoximetasone) Cream USP, 0.05% due to subpotent drug issues. Check lot A5192-18338.
Use caution until it’s fixed
Subpotent Drug
Contact the company
What happened, in plain English
Taro Pharmaceuticals U.S.A., Inc. is recalling Topicort (desoximetasone) Cream USP, 0.05%, packaged in 5 g tubes because it is a subpotent drug. The affected product was distributed as professional samples only and is prescription-only. This recall involves 62,800 tubes distributed in several U.S. states. Read more at govinfonow.com/recall/43022-taro-recalls-topicort-cream-due-to-subpotent-drug-hazard.
Source Summary by GovInfoNow · govinfonow.com/recall/43022-taro-recalls-topicort-cream-due-to-subpotent-drug-hazard · Updated October 11, 2026 · FDA enforcement record: FDA #D-0950-2016
Cite this page
“Taro Recalls Topicort Cream Due to Subpotent Drug Hazard.” GovInfoNow, updated October 11, 2026. https://govinfonow.com/recall/43022-taro-recalls-topicort-cream-due-to-subpotent-drug-hazard. Based on FDA recall #D-0950-2016 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0950-2016%22&limit=1).
Why it’s dangerous
The cream is classified as a subpotent drug, meaning it may not contain enough active ingredient to be effective for treating skin conditions. Using an ineffective medication can lead to untreated symptoms or delayed proper treatment.
Who’s affected
Individuals who received professional samples of Topicort Cream from healthcare providers. The risk applies to those using the specific lot number identified in the recall.
How to tell if you have this one
Check if you have Topicort (desoximetasone) Cream USP, 0.05% in 5 g tubes distributed by Taro Pharmaceuticals. Specifically look for NDC 51672-5205-5 and Lot # A5192-18338 with an expiry date of 12/2016.
- Brand
Taro Pharmaceuticals- Category
Drug
What to do — step by step
Check Your Product
Verify if your cream matches the recalled NDC 51672-5205-5 and Lot # A5192-18338.
Contact Your Provider
Speak with your healthcare provider or pharmacist about the subpotent drug issue and next steps.
Where it went and when
Where it was distributed
Distributed in 9 states.
FDA distribution: “U.S. Including: CA, CT, MA, MD, NY, NJ, OK, TX, and WA” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: California, Connecticut, Maryland, Massachusetts, New Jersey, New York, Oklahoma, Texas, Washington.
Recall timeline
FDA terminated this recall 2.2 years after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0950-2016 (March 31, 2016) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0950-2016 to see it in context.
- Plain-language summary written by qwen3.6:35b-a3b on October 11, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.